Scalable, High-Throughput Platform to Offer Unprecedented Insight into Gene Expression of Individual Cells
Most scientific studies rely on analysis of bulk tissue samples. These samples are usually composed of multiple cell types with varying functions. Gene expression data is averaged across cells, making it difficult to identify differences between cells and to understand the role of cell variation. Single-cell sequencing addresses those challenges and provides deeper insight into cell function, disease progression and therapeutic response. These data can be important in studies of neurological tissues, for example, which are known to have hundreds of specialized cell types.
Using Bio-Rad’s best-in-class droplet partitioning technology and Illumina’s leading NGS technologies, the new solution is optimized to isolate and barcode single cells for downstream sequencing. Data analysis is conducted via BaseSpace, Illumina’s cloud-based genomics computing environment. The solution will be scalable to isolate significantly larger numbers of single cells compared to commercially available solutions today, in just a few minutes at a cost-effective price.
“We welcome the opportunity to collaborate with
“By collaborating with
The companies expect to launch the solution in late 2016 or early 2017.
Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as the global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture and other emerging segments. To learn more, visit www.illumina.com and follow @illumina.
Illumina Forward-Looking Statements
This release contains forward-looking statements that involve risks and uncertainties, such as Illumina’s expectations regarding the launch of any products. Important factors that could cause actual results to differ materially from those in forward-looking statements include the application of generally accepted accounting principles, which are highly complex and involve many subjective assumptions, estimates, and judgments, and the other factors detailed in Illumina’s filings with the
Bio-Rad Forward-Looking Statements
This release may be deemed to contain certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements we make regarding our development and launch of new products. Forward-looking statements generally can be identified by the use of forward-looking terminology such as, “believe,” “expect,” “anticipate,” “may,” “will,” “intend,” “estimate,” “continue,” or similar expressions or the negative of those terms or expressions, although not all forward-looking statements contain these words. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. These risks and uncertainties include our ability to develop and market new or improved products, problems we may encounter with our supply chain and product quality issues. For further information regarding our risks and uncertainties, please refer to the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operation” in Bio-Rad’s public reports filed with the
Bio-Rad Laboratories, Inc.
Tina Cuccia, Corporate Communications